These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 38291678)
1. Pembrolizumab-induced agranulocytosis. Fernández Martínez V; García-Avello Fernández-Cueto A; Valencia Soto CM; Barbadillo Villanueva S; Ochagavía Sufrategui M; Rioja Carrera M; Alonso Buznego LA; Valero Domínguez M J Oncol Pharm Pract; 2024 Jun; 30(4):767-771. PubMed ID: 38291678 [TBL] [Abstract][Full Text] [Related]
2. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition. Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704 [TBL] [Abstract][Full Text] [Related]
3. Successful Steroid Treatment of Pembrolizumab-induced Agranulocytosis That Developed after Splenectomy in a Patient with Non-small-cell Lung Cancer. Okuzumi S; Kamata H; Emoto K; Shimizu T; Otake S; Irie H; Chubachi S; Ikemura S; Yasuda H; Fukunaga K Intern Med; 2023 Jul; 62(14):2113-2121. PubMed ID: 36450461 [TBL] [Abstract][Full Text] [Related]
4. Delayed immune-related neutropenia with hepatitis by pembrolizumab. Nakako S; Nakashima Y; Okamura H; Tani Y; Ueda T; Makuuchi Y; Kuno M; Takakuwa T; Nishimoto M; Koh H; Nakamae H; Hino M Immunotherapy; 2022 Feb; 14(2):101-105. PubMed ID: 34758635 [TBL] [Abstract][Full Text] [Related]
5. Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol. Liu Y; Zhang J; Yin Z; Zhu X; Xue L; Cao B Thorac Cancer; 2020 Jul; 11(7):2023-2030. PubMed ID: 32379397 [TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab-induced severe oral mucositis in a patient with squamous cell carcinoma of the lung: A case study. Yoon SY; Han JJ; Baek SK; Kim HJ; Maeng CH Lung Cancer; 2020 Sep; 147():21-25. PubMed ID: 32652370 [TBL] [Abstract][Full Text] [Related]
7. A case of non-small cell lung cancer with danazol-dependent aplastic anemia induced by pembrolizumab. Goda S; Tsuji T; Matsumoto Y; Shiotsu S; Tanaka S; Suga Y; Fujii H; Matsuyama A; Omura A; Yuba T; Takumi C; Hiraoka N Curr Probl Cancer; 2021 Jun; 45(3):100686. PubMed ID: 33293197 [TBL] [Abstract][Full Text] [Related]
8. First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset. Satouchi M; Nosaki K; Takahashi T; Nakagawa K; Aoe K; Kurata T; Sekine A; Horiike A; Fukuhara T; Sugawara S; Umemura S; Saka H; Okamoto I; Yamamoto N; Sakai H; Kishi K; Katakami N; Horinouchi H; Hida T; Okamoto H; Atagi S; Ohira T; Han SR; Noguchi K; Ebiana V; Hotta K Cancer Sci; 2020 Dec; 111(12):4480-4489. PubMed ID: 32926507 [TBL] [Abstract][Full Text] [Related]
9. A case of severe Pembrolizumab-induced neutropenia. Barbacki A; Maliha PG; Hudson M; Small D Anticancer Drugs; 2018 Sep; 29(8):817-819. PubMed ID: 29889673 [TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. Leighl NB; Hellmann MD; Hui R; Carcereny E; Felip E; Ahn MJ; Eder JP; Balmanoukian AS; Aggarwal C; Horn L; Patnaik A; Gubens M; Ramalingam SS; Lubiniecki GM; Zhang J; Piperdi B; Garon EB Lancet Respir Med; 2019 Apr; 7(4):347-357. PubMed ID: 30876831 [TBL] [Abstract][Full Text] [Related]
11. Dramatic, significant metabolic response to a one-time pembrolizumab treatment following a relapse of pre-existing organizing pneumonia in a patient with advanced non-small cell lung cancer: A case report. Kato M; Mori M; Miura K; Asao T; Motomura H; Nishino K; Ko R; Koyama R; Hayashi T; Takahashi K Thorac Cancer; 2021 Nov; 12(22):3076-3079. PubMed ID: 34617405 [TBL] [Abstract][Full Text] [Related]
12. Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab. Basnet S; Dhital R; Tharu B Medicina (Kaunas); 2019 May; 55(5):. PubMed ID: 31117208 [TBL] [Abstract][Full Text] [Related]
13. Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab Following Tubulointerstitial Nephritis Due to Pembrolizumab. Taki T; Oda N; Fujioka Y; Mitani R; Tokura T; Takata I; Oshiro Y; Takigawa N Intern Med; 2020 Jul; 59(13):1639-1642. PubMed ID: 32269191 [TBL] [Abstract][Full Text] [Related]
14. [A case of meningoencephalitis associated with pembrolizumab treated for squamous cell lung cancer]. Yonenobu Y; Ishijima M; Toyooka K; Fujimura H Rinsho Shinkeigaku; 2019 Feb; 59(2):105-108. PubMed ID: 30700688 [TBL] [Abstract][Full Text] [Related]
15. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962 [TBL] [Abstract][Full Text] [Related]